link to homepage

Institute of Complex Systems
ICS Key Visual

Navigation and service


Prof. Dieter Willbold links auf einer Treppe stehend, rechts im Bild ein Ausschnitt eines 900-Mhz-NMR-Spektrometers, das in Willbolds Forschung zur Anwendung kommt.
Phase I Clinical Trials Approved for Alzheimer’s Drug Candidate
Jülich, 20 March 2018 – In what represents a first milestone on the road to application, the drug candidate for the treatment of Alzheimer’s disease, PRI-002, has received approval for phase I clinical trials. At an independent clinic, the potential Alzheimer’s drug will initially be assessed under strict requirements to see whether it is safe for humans. The drug was developed at Forschungszentrum Jülich and Heinrich Heine University Düsseldorf. In September 2017, Priavoid GmbH was founded as a spin-off of Forschungszentrum Jülich with the aim of launching the drug on market.
More: Phase I Clinical Trials Approved for Alzheimer’s Drug Candidate …




Within the JARA research alliance, the JARA-SOFT group undertakes multi-disciplinary soft matter research to address current open questions in material sciences and biophysics. More: JARA-SOFT …